Related Experiment Video
Updated: Oct 21, 2025

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Recurrent arteriovenous graft thrombosis in COVID-19 positive patient
Anil Kumar Singh1, Saurabh Bansal2, Namrata Singhania3
1Department of Internal Medicine Geisinger Community Medical Center Scranton Pennsylvania USA.
Insights
COVID-19 can cause hypercoagulability, increasing the risk of blood clots. This may lead to complications like recurrent arteriovenous graft thrombosis in patients.
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Hematology
Background:
- COVID-19 is frequently associated with a hypercoagulable state.
- This hypercoagulability contributes to various thromboembolic events.
Observation:
- Patients with COVID-19 exhibit increased coagulability.
- This pathophysiology can manifest as recurrent thrombosis in arteriovenous grafts.
Findings:
- Hypercoagulability is a significant complication of COVID-19.
- Arteriovenous graft thrombosis is a potential consequence of COVID-19-induced hypercoagulability.
Implications:
- Understanding this link is crucial for managing COVID-19 patients.
- Proactive monitoring and management of coagulation may prevent graft thrombosis.
Abstract:
Hypercoagulability is one of the common complications seen in COVID-19. It can lead to multiple thromboembolic complications. Recurrent arteriovenous graft thrombosis can be one of complications from this pathophysiology.
More Related Videos
Related Concept Videos
Hemodialysis I: Introduction
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis IV: Nursing Management

